May 18, 2026: FDA warns 503B compounding pharmacy for producing tirzepatide after shortage ended Major Stories Read FDA's warning letter The FDA issued a warning letter to ProRx, citing its production of tirzepatide, which is not eligible for compounding
In a statement shared with Fox News Digital, a Novo Nordisk spokesperson said the drugmaker is committed to working with regulators, law enforcement and "other key stakeholders" to ensure "affordable access to safe, effective and FDA-approved GLP-1 obesity medication like Wegovy and to protect patients from unapproved and untested knockoff drugs." "The desire to function at our highest level is something that we all feel." "Novo Nordisk supports FDAs recent thorough scientific analysis and conclusion that there is no medical basis or clinical need for the continued mass compounding of unapproved semaglutide and liraglutide drugs," they went on
Selecting the best glutathione tablets for skin whitening is a crucial process to guarantee safety and effectiveness
The FDA and patients have been caught in the middle of a fight between the makers of branded drugs used to treat obesity and pharmacies that have been compounding cheaper versions of those drugs for more than two years
Ensuring you take B12 only after a full meal to aid absorption